Missense Variants of Uncertain Significance (VUS) Altering the Phosphorylation Patterns of BRCA1 and BRCA2

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Tram, Eric ^a,c   Savas, Sevtap ^a,c,d   Ozcelik, Hilmi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ALGORITHM; ARTICLE; BINDING SITE; BREAST CANCER; CELL CYCLE REGULATION; DNA DAMAGE; DNA REPAIR; GENETIC CONSERVATION; HUMAN; IN VIVO STUDY; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; CONSERVED SEQUENCE; EVOLUTION, MOLECULAR; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHOSPHORYLATION; PHYLOGENY; SEQUENCE ALIGNMENT; SOFTWARE;

EID: 84877948964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062468     Document Type: Article

References (74)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792.
3. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, et al. (1994) Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8: 399-404.
4. Fackenthal JD, Olopade OI, (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7: 937-948.
5. Ramus SJ, Gayther SA, (2009) The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 3: 138-150.
6. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, et al. (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11: 198-200.
7. Hayes F, Cayanan C, Barilla D, Monteiro AN, (2000) Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res 60: 2411-2418.
8. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA, (2003) Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci U S A 100: 1151-1156.
9. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, et al. (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41: 492-507.
10. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, et al. (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43: 295-305.
11. Phelan CM, Dapic V, Tice B, Favis R, Kwan E, et al. (2005) Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 42: 138-146.
12. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, et al. (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10: 353-360.
13. Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, et al. (1997) Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. Proc Natl Acad Sci U S A 94: 5820-5825.
14. Millot GA, Carvalho MA, Caputo SM, Vreeswijk MP, Brown MA, et al. (2012) A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat 33: 1526-1537.
15. Thompson D, Easton DF, Goldgar DE, (2003) A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73: 652-655.
16. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, et al. (2007) A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. American journal of human genetics 81: 873-883.
17. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN, (2004) Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64: 3790-3797.
18. Monteiro AN, Couch FJ, (2006) Cancer risk assessment at the atomic level. Cancer Res 66: 1897-1899.
19. Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, et al. (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67: 1494-1501.
20. Johnson LN, O'Reilly M, (1996) Control by phosphorylation. Curr Opin Struct Biol 6: 762-769.
21. Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnica-Worms H, et al. (1994) Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol 4: 973-982.
22. Kreegipuu A, Blom N, Brunak S, Jarv J, (1998) Statistical analysis of protein kinase specificity determinants. FEBS Lett 430: 45-50.
23. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S, (2004) Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4: 1633-1649.
24. Savas S, Ozcelik H, (2005) Phosphorylation states of cell cycle and DNA repair proteins can be altered by the nsSNPs. BMC Cancer 5: 107.
25. Savas S, Taylor IW, Wrana JL, Ozcelik H, (2007) Functional nonsynonymous single nucleotide polymorphisms from the TGF-beta protein interaction network. Physiol Genomics 29: 109-117.
26. Linding R, Jensen LJ, Pasculescu A, Olhovsky M, Colwill K, et al. (2008) NetworKIN: a resource for exploring cellular phosphorylation networks. Nucleic Acids Res 36: D695-699.
27. Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B, (2004) PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4: 1551-1561.
28. Diella F, Gould CM, Chica C, Via A, Gibson TJ, (2008) Phospho.ELM: a database of phosphorylation sites - update 2008. Nucleic Acids Res 36: D240-244.
29. Obenauer JC, Cantley LC, Yaffe MB, (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 3635-3641.
30. Hjerrild M, Stensballe A, Rasmussen TE, Kofoed CB, Blom N, et al. (2004) Identification of phosphorylation sites in protein kinase A substrates using artificial neural networks and mass spectrometry. J Proteome Res 3: 426-433.
31. von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, et al. (2007) STRING 7- recent developments in the integration and prediction of protein interactions. Nucleic Acids Res 35: D358-362.
32. Ng PC, Henikoff S, (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814.
33. Ramensky V, Bork P, Sunyaev S, (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900.
34. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD, (2004) Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23: 2009-2015.
35. Cohen P, (2000) The regulation of protein function by multisite phosphorylation - a 25 year update. Trends Biochem Sci 25: 596-601.
36. Pawson T, (2004) Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116: 191-203.
37. Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, et al. (2000) Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res 60: 3299-3304.
38. Gatei M, Zhou BB, Hobson K, Scott S, Young D, et al. (2001) Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J Biol Chem 276: 17276-17280.
39. Xu B, O'Donnell AH, Kim ST, Kastan MB, (2002) Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 62: 4588-4591.
40. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, et al. (2004) Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 24: 708-718.
41. Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV, et al. (2004) Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet 13: 2061-2074.
42. Moritz A, Li Y, Guo A, Villen J, Wang Y, et al. (2010) Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 3: ra64.
43. Hinton CV, Fitzgerald LD, Thompson ME, (2007) Phosphatidylinositol 3-kinase/Akt signaling enhances nuclear localization and transcriptional activity of BRCA1. Exp Cell Res 313: 1735-1744.
44. Esashi F, Christ N, Gannon J, Liu Y, Hunt T, et al. (2005) CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434: 598-604.
45. Davies OR, Pellegrini L, (2007) Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat Struct Mol Biol 14: 475-483.
46. Au WW, Henderson BR, (2007) Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage. Cell Signal 19: 1879-1892.
47. Ruffner H, Jiang W, Craig AG, Hunter T, Verma IM, (1999) BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol 19: 4843-4854.
48. Kehn K, Berro R, Alhaj A, Bottazzi ME, Yeh WI, et al. (2007) Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. Oncogene 26: 5060-5069.
49. Cortez D, Wang Y, Qin J, Elledge SJ, (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286: 1162-1166.
50. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, et al. (2004) BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 279: 19643-19648.
51. Nigg EA, (2002) Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2: 815-825.
52. Sankaran S, Crone DE, Palazzo RE, Parvin JD, (2007) Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Res 67: 11186-11194.
53. Marx J, (2001) Cell biology. Do centrosome abnormalities lead to cancer? Science 292: 426-429.
54. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, et al. (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A 99: 1978-1983.
55. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160-1166.
56. Lin HR, Ting NS, Qin J, Lee WH, (2003) M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex. J Biol Chem 278: 35979-35987.
57. Liu J, Doty T, Gibson B, Heyer WD, (2010) Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol 17: 1260-1262.
58. Loizou JI, El-Khamisy SF, Zlatanou A, Moore DJ, Chan DW, et al. (2004) The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell 117: 17-28.
59. O'Brien KA, Lemke SJ, Cocke KS, Rao RN, Beckmann RP, (1999) Casein kinase 2 binds to and phosphorylates BRCA1. Biochem Biophys Res Commun 260: 658-664.
60. Pepperkok R, Lorenz P, Ansorge W, Pyerin W, (1994) Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J Biol Chem 269: 6986-6991.
61. Chen L, Giorgianni F, Beranova-Giorgianni S, (2010) Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J Proteome Res 9: 174-178.
62. Gu TL, Deng X, Huang F, Tucker M, Crosby K, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6: e15640.
63. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
64. Rush J, Moritz A, Lee KA, Guo A, Goss VL, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94-101.
65. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105: 10762-10767.
66. Bennetzen MV, Larsen DH, Bunkenborg J, Bartek J, Lukas J, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9: 1314-1323.
67. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3: ra3.
68. Botuyan MV, Nomine Y, Yu X, Juranic N, Macura S, et al. (2004) Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure 12: 1137-1146.
69. Manke IA, Lowery DM, Nguyen A, Yaffe MB, (2003) BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302: 636-639.
70. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH, (2000) hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404: 201-204.
71. Carvalho MA, Couch FJ, Monteiro AN, (2007) Functional assays for BRCA1 and BRCA2. Int J Biochem Cell Biol 39: 298-310.
72. Aaroe J, Lindahl T, Dumeaux V, Saebo S, Tobin D, et al. (2010) Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res 12: R7.
73. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311.
74. Chen RQ, Yang QK, Lu BW, Yi W, Cantin G, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69: 2663-2668.